Results 81 to 90 of about 8,071 (187)

Partial-wave analysis of the eta pi+ pi- system produced in the reaction pi-p --> eta pi+ pi- n at 18 GeV/c

open access: yes, 2000
A partial-wave analysis of 9082 eta pi+ pi- n events produced in the reaction pi- p --> eta pi+ pi- n at 18.3 GeV/c has been carried out using data from experiment 852 at Brookhaven National Laboratory.
A. A. Yershov   +78 more
core   +1 more source

Identification of Orthosteric and Allosteric Pharmacological Chaperones for Mucopolysaccharidosis Type IIIB

open access: yesChemBioChem, Volume 25, Issue 15, August 1, 2024.
We modeled substrate interactions in NAGLU′s active site and predicted allosteric sites. Virtual screening against a human‐tested molecule database identified potential pharmacological chaperones (PCs). In vitro evaluations confirmed their binding to NAGLU and ability to restore enzymatic activity in MPS IIIB fibroblasts with mutant enzymes.
Juan Camilo Losada   +6 more
wiley   +1 more source

Atypical presentation of mucopolysaccharidosis type IVA

open access: yesMolecular Genetics and Metabolism Reports, 2016
A 14 year old patient with short stature, type I diabetes, and cataracts was referred for evaluation of avascular necrosis of the femoral head. Radiography was suggestive of spondyloepiphyseal dysplasia with decreased bone mineral density for age ...
Eric T. Rush
doaj   +1 more source

Pain management challenges in a patient with mucopolysaccharidosis IVA

open access: yesClinical Case Reports, Volume 12, Issue 8, August 2024.
Key Clinical Message It is important to consider all potential pain management modalities including alternative treatment on managing complex pain presentations. Acupuncture is a treatment modality that may result in reduction of pain in patients with significant medical comorbidities due to MPS IVA.
Marcus Gurgius   +2 more
wiley   +1 more source

Delayed diagnosis of mild mucopolysaccharidosis type IVA

open access: yesBMC Medical Genomics
Background Mucopolysaccharidosis IVA (MPS IVA) is a lysosomal storage disease caused by biallelic variants in the N-acetylgalactosamine-6-sulfatase (GALNS) gene and is characterized by progressive and multi-system involvements, dominantly with skeletal ...
Mengni Yi, Pinquan Shen, Huiwen Zhang
doaj   +1 more source

Perthes-Like Disease Masquerading Non-Classical MPS

open access: yesJournal of Inborn Errors of Metabolism and Screening, 2020
Mucopolysaccharidoses (MPS) are inborn errors of metabolism caused by deficient lysosomal enzymes, leading to organomegaly, hip osteonecrosis, coarse facial features, bone deformities, joint stiffness, cardiac and pulmonary symptoms (MPS VI) or ...
Carolina F.M. Souza   +12 more
doaj   +1 more source

Synthesis and Structural Design of Graphene, Silicon and Silicon‐Based Materials Including Incorporation of Graphene as Anode to Improve Electrochemical Performance in Lithium‐Ion Batteries

open access: yesAdvanced Materials Interfaces, Volume 11, Issue 19, July 5, 2024.
This review delves into cutting‐edge methods for optimizing Si‐based anodes, focusing on design and synthesis of composite materials, particularly with graphene. By meticulously enhancing structural features, the review unveils transformative design paradigms that significantly improve performance. Gain insights into the latest advancements, understand
Jawad Reslan   +2 more
wiley   +1 more source

Safety and physiological effects of two different doses of elosulfase alfa in patients with morquio a syndrome: A randomized, double-blind, pilot study. [PDF]

open access: yes, 2015
The primary treatment outcomes of a phase 2, randomized, double-blind, pilot study evaluating safety, physiological, and pharmacological effects of elosulfase alfa in patients with Morquio A syndrome are herewith presented.
Berger, Kenneth I   +14 more
core   +1 more source

Family reflections: MPS IVA [PDF]

open access: yesPediatric Research, 2018
Mary Cavanagh   +2 more
openaire   +1 more source

Abstracts

open access: yesMolecular Oncology, Volume 19, Issue S1, Page 1-940, June 2025.
Abstracts submitted to the ‘EACR 2025 Congress: Innovative Cancer Science’, from 16–19 June 2025 and accepted by the Congress Organising Committee are published in this Supplement of Molecular Oncology, an affiliated journal of the European Association for Cancer Research (EACR).
wiley   +1 more source

Home - About - Disclaimer - Privacy